GlassScriptPhysician profile
Duane Edward Banet
NPI 1245211937
$1,557.37
in general payments reported to CMS, 2019-2025
16 companies · $47.29 in 2025
The $47.29 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $214 · 2021: $353 · 2022: $213 · 2023: $388 · 2024: $212 · 2025: $47.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $681.48 | 2019-2023 | Tremfya |
| Abbvie INC. | $564.12 | 2020-2024 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $117.49 | 2022-2025 | |
| Leo Pharma INC. | $31.89 | 2022-2025 | Adbry |
| Biofrontera INC. | $20.93 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $19.78 | 2023 | Sotyktu |
| Allergan, INC. | $18.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2023 | Spevigo |
| Genzyme Corporation | $15.99 | 2020 | |
| Ucb, INC. | $15.82 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.45 | 2024 | Zoryve |
| Amgen INC. | $13.83 | 2019 | |
| Genentech USA, INC. | $13.68 | 2021 | |
| Prugen, INC. Pharmaceuticals | $11.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Banet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.